Investment Rating - The report does not provide a specific investment rating for Samsung Biologics [1] Core Insights - Samsung Biologics achieved a revenue growth of 30.3% in 2025, exceeding the previous guidance of 25-30%. The revenue growth guidance for 2026 is set at 15-20%, with potential upward revisions due to contributions from the U.S. facility and foreign exchange movements. The cumulative contract value surpassed USD 21.2 billion by the end of 2025 [2][4] - The company is focused on capacity expansion, particularly with the new U.S. facility and Plant 5 in Korea, which is expected to achieve high utilization rates once commercial production begins [2][4] - Samsung Biologics differentiates itself in the biologics manufacturing sector through superior quality, achieving a batch success rate of 99% compared to the industry average of 95%, and faster delivery times, completing plant construction in 24 months versus the industry average of 3-4 years [3][5] Summary by Sections 2025 Performance Review and 2026 Outlook - Samsung Biologics reported a revenue growth of 30.3% in 2025, with a cumulative contract value exceeding USD 21.2 billion. The company has set a revenue growth guidance of 15-20% for 2026, which may be revised upwards post-acquisition of the U.S. facility [2][4] Strategic Priorities for Plant 5 and the New U.S. Facility - The new U.S. facility is expected to start commercial production in Q2 2026, with plans for equipment upgrades and potential expansion from 60,000 liters to 200,000 liters. Plant 5 in Korea is on track to achieve over 80% utilization after ramp-up [2][4] Differentiation in Biologics Manufacturing - Samsung Biologics views Lonza and Fujifilm as key competitors and focuses on quality and speed as differentiators. The company employs a "cookie-cutter" model for plant construction, allowing for quicker market entry [3][5] Strategy and Outlook for ADCs and Other New Modalities - The company is well-positioned to capture market share in the ADC sector, with plans to offer end-to-end services starting in Q1 2027. The dedicated ADC facility is already under construction [5] U.S. vs. Korea Manufacturing Pricing - Manufacturing costs in the U.S. are higher due to labor costs being approximately double those in Korea. Samsung Biologics plans to pass some of these costs onto clients, anticipating lower margins for U.S. operations compared to its Korean facility [5] Long-Term Industry Capacity Oversupply - The company does not foresee a significant supply overhang in the industry for at least the next five years, citing stagnant productivity from large pharmaceutical companies and a continued trend towards outsourcing as key factors sustaining demand for CDMO services [2][5]

Group 1 - The company, Shiyao Innovation, has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities as its sole sponsor [1] - The company focuses on innovative therapies targeting unmet clinical needs in significant disease areas such as oncology, autoimmune diseases, and infectious diseases [1] - The company plans to commercialize two antibody drugs in the second half of 2024, including a first-class innovative drug and a biosimilar [1] Group 2 - Since its establishment in 2006, the company has specialized in the research and production of high-quality caffeine, becoming the largest producer of chemically synthesized caffeine globally [1] - The company expanded its main business into the health food sector in 2016, launching a comprehensive range of health food products, with its trademark recognized as a famous Chinese brand [2] - The global and Chinese pharmaceutical markets are experiencing significant growth, with the ADC market in China expected to expand from RMB 3.9 billion in 2024 to RMB 158.6 billion by 2035 [2]

Core Viewpoint - InnoCare Pharma-B (09606) is planning to list on the STAR Market, pending market conditions and further approvals from the board and shareholders, following a successful IPO on the Hong Kong Stock Exchange that raised over HKD 1.5 billion [1] Group 1: Company Developments - InnoCare Pharma's stock price increased by 5% in early trading, reaching HKD 345.6 with a trading volume of HKD 599 million [1] - The company was listed on the Hong Kong Stock Exchange on April 15, raising over HKD 1.5 billion, marking it as one of the largest IPOs in the Hong Kong 18A sector in the past four years [1] - The stock price peaked at HKD 563.5 in September, reflecting a maximum increase of 495.67% from the IPO price of HKD 94.6 per share [1] Group 2: Industry Insights - According to a report by CICC, the global ADC market is projected to reach approximately USD 10.4 billion in 2023 and is expected to grow to USD 115.1 billion by 2032 [1] - InnoCare Pharma plans to submit applications for its DB-1303 (HER2 ADC) for endometrial cancer in the U.S. and for breast cancer in China by 2025 [1] - The company’s DB-1311 (B7-H3 ADC) shows potential as a best-in-class candidate for prostate cancer, while DB-1310 (HER3 ADC) is expected to follow suit; DB-1305 (TROP2 ADC) and dual antibody explorations are leading globally in next-generation ADC research [1]